define({"menu_home":"Westvac","menu_news":"Media","menu_team":"Our Team","menu_join":"Career","menu_about":"About Us","menu_product":" Product R＆D","menu_promotion":"Commercialization","menu_contact":"Contact Us","menu_video":"Company Video","menu_culture":"WestVac Culture","keywords":"成都威斯克生物医药有限公司，威斯克生物，威斯克，四川大学华西医院，四川大学生物治疗国家重点实验室，魏于全，生物医药，传染性疾病，恶性肿瘤，mRNA疫苗，新冠病毒，肺炎，疫苗，昆虫细胞，重组蛋白，重组蛋白疫苗，免疫治疗","description":"WestVac Biopharma is founded by Academician Wei Yuquan from West China Hospital of Sichuan University, together with 10 scientists from State Key Laboratory of Biotherapy(SKLB). Its headquarter is located in the International Bio-Town, Chengdu. The CEO of WestVac Biopharma is Prof.Wei Yuquan, who is the Academician of Chinese Academy of Sciences as well as the Director of State Key Laboratory of Biotherapy.WestVac is committed to exploring the latest biotherapy technologies for major diseases, including infectious diseases, malignant tumors, cardiovascular diseases, and so on. It has attached great importance in the Research and Development(R&D) of COVID-19 vaccine especially and building a COVID-19 vaccine production platform. State Key Laboratory of Biotherapy (SKLB) was established by the Ministry of Sciences and Technology of China in 2005 and became one of the National R&D Platforms for Novel Drugs founded by the Ministries of Sciences and Technology as well as that of Health of China in 2008. It is also supported by National Collaborative Innovation Program and has become the National Collaborative Innovation Center for Biotherapy since 2013.West China Hospital of Sichuan University，founded in 1892, is the National Center for Diagnosis and Treatment of Severe and Critical Diseases in Western China. It is also the world’s largest comprehensive hospital complex located in one campus area.Relying on the medical resources of State Key Laboratory of Biotherapy and West China Medical Center, WestVac has adopted recombinant protein methodology to develop the COVID-19 vaccine. Because of the safety of the protein vaccine , it is also the only COVID-19 vaccine approved for the use in children over 3 years old in China.The vaccine was approved by the National Medical Products Administration for clinical trials on August 21,2020. Phase I\/II clinical trials have been completed, and phase III clinical trials are being carried out in Nepal, Kenya, Japan and other countries.The vaccine targets the spike protein binding domain (S-RBD) of SARS-CoV-2, producing neutralizing antibodies to block COVID-19 infection of human cells. The result was published on Nature, the world’s famous scientific journal on July 29th, 2020. It has also been the first paper of COVID vaccine published by Nature since the pandemic outbreak. The S-RBD gene of the COVID-19 virus is introduced into the insect cells, which were used as a factory to produce high-quality recombinant vaccine protein and then does refined purification. Such technology is easy to be mass-produced and brought to the market.WestVac Biopharma is committed to becoming the world`s leading vaccine and immunotherapy platform.","text_about":"WestVac BioPharma Co., Ltd. (hereinafter referred to as \"WestVac BioPharma\") is an innovative biopharmaceutical enterprise integrating vaccine R&D, production and sales. The company’s registered capital is 1.242 billion yuan. With the continuous investment and support of many powerful shareholders -- CICC Capital, Haier Biomedical, Shanghai Pharma, Sichuan Development Holding, China Taiping and so on, WestVac BioPharma has been successfully selected into the list of unicorn companies in 2021.
\r\n\r\nWestVac BioPharma was founded by more than 10 scientists from the State Key Laboratory of Biotherapy of West China Hospital of Sichuan University under the leadership of Academician WEI Yuquan. In terms of production, quality, operations management, etc., WestVac Biopharma has introduced advanced talents from well-known domestic and international vaccine companies, established a complete production and quality management system, has more than 300 employees to ensure large scale production of vaccines can proceed smoothly.
\r\n\r\nCurrently, WestVac Biopharma has a mature insect cell expression platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine and immunotherapy platform, with more than 30 pipelines including COVID-19 vaccine, multivalent influenza vaccine, herpes virus vaccine, acne vaccine, tumor immunity preparations.
\r\n\r\nPhase III clinical trials of the first generation Recombinant COVID-19 Vaccine (Sf9 cells) have been conducted globally in multiple countries, with nearly 40,000 subjects enrolled and vaccinated, and completed clinical trials in Japan for marketing purposes. It is the first Chinese COVID-19 vaccine that entered clinical trials in a developed country. Study results show that the vaccine has good safety and immunogenicity, and can obviously induce neutralizing antibodies against COVID-19 virus prototype strain and variant strains, which fully embodies the advantages and characteristics of recombinant protein vaccine technology route.
\r\n\r\nMeanwhile, the second generation Recombinant COVID-19 Vaccine (Sf9 cells) developed by WestVac BioPharma with a high titer neutralizing antibody has achieved significant progresses against COVID-19 mutant strains including Omicron and Delta. The vaccine belongs to the latest fifth generation vaccine technology (fully synthetic vaccine), targeting the S-RBD protein of the COVID-19 mutant strain, the subunit vaccine antigen is precisely designed based on the structure, which can self-assemble into stable protein particles. The large-scale production of vaccines adopts internationally advanced insect cell production technology and combined with oil-in-water emulsion adjuvant (MF59-like adjuvant) that induces a stronger immune response. It is one of the first COVID-19 vaccines announced internationally that has high titers of neutralizing antibodies against the Omicron mutant strain. The application materials have been submitted to the National Medical Products Administration in August, 2021, and it is expected to officially enter clinical trials in early 2022.
\r\n\r\nIn addition, WestVac BioPharma is also developing a nasal spray version of COVID-19 vaccine, new oral anti-COVID-19 drug, and mRNA COVID-19 vaccine. The current research results show that the three products have good in vivo safety and activity.
\r\n\r\nWestVac Biopharma has built a production base with an annual production capacity of 600 million doses in Chengdu Tianfu International Bio-town, has completed the construction and verification of GMP production workshop, and obtained the \"Drug Manufacturing License\". In addition, Guangzhou production base with an annual capacity of 500 million doses is also under construction. WestVac Biopharma has also established a good communication with many international organizations such as the World Health Organization (WHO), Gates Foundation, PATH, The Coalition for Epidemic Preparedness Innovations (CEPI) and so on.
\r\n\r\n In the future, WestVac Biopharma will continue to persist in the corporate philosophy of \"We Initiate Science & Technology Value, Always for Caring\", so that innovative vaccines and immunotherapy will go from China to the world, and defend the brilliance of more lives!","text_product":"WestVac BioPharma Co., Ltd. (hereinafter referred to as \"WestVac BioPharma\") has a mature insect cell expression platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine and immunotherapy platform, with more than 30 pipelines including COVID-19 vaccine, multivalent influenza vaccine, herpes virus vaccine, acne vaccine, tumor immunity preparations.
\r\n\t\t\r\n After the outbreak of COVID-19 in early 2020, with the strong support of governments at all levels, Sichuan University West China Medical Center and WestVac BioPharma took the initiative to participate in the scientific and technological action against COVID-19, and made breakthroughs through more than one year's efforts. Affiliated to Sichuan University, West China Medical Center is the largest national medical center in western China. Its State Key Laboratory of Biotherapy is the only laboratory of its kind with the mandate of \"Treating Critical Human Disease with Biotechnology\". There are over 150 experts with multi-disciplinary background, including 13 Chang Jiang Scholars\/Young Chang Jiang Scholars and 18 winners of the National Science Fund for Distinguished Young Scholars.
\r\n\t\t\r\n\t\tUnder the joint Prevention and Control Mechanism of The State Council, Sichuan University and WestVac BioPharma jointly undertook the research and development of Recombinant COVID-19 Vaccine (Sf9 cells), a national key scientific research project. Led by Professor WEI Yuquan, Academician of the Chinese Academy of Sciences, Director of the State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, and Chairman of WestVac BioPharma, and his team of scientists, the project belongs to one of the five state-funded COVID-19 vaccine development technology routes.
\r\n\t\t\r\n\t\tOn July 29, 2020, WestVac Biopharma R&D team published the first COVID-19 vaccine research paper in the journal Nature<\/a>. They used an innovative recombinant protein technology route for R&D. It's China's first recombinant subunit COVID-19 vaccines expressed in insect cells. S protein of SARS-CoV-2 was prepared by introducing SARS-CoV-2 genes into insect cells which can induce human body to produce antibodies to block viral infection. Large production of protein has been achieved.
\r\n\t\t\r\n\t\tThe Phase I and II clinical trials of Coviccine have been completed in June 2021. Currently, Phase III clinical trials are progressing smoothly in Mexico, the Philippines, Indonesia, Kenya and other countries, and nearly 40,000 subjects have been enrolled and vaccinated, and required clinical trials have been completed in Japan. It is the first Chinese COVID-19 vaccine that entered clinical trials in a developed country. Primary research results show that the vaccine has good safety and immunogenicity, and can evidently induce neutralizing antibodies against the prototype and variant strains of SARS-CoV-2, which fully reflects the advantages and characteristics of the recombinant protein vaccine technology. Furthermore, using Coviccine as the third dose in sequential vaccination after using existing COVID-19 vaccines on the market significantly increased neutralizing antibody titers against multiple variant strains such as Omicron, Delta and other variants.
\r\n\t\t\r\n\t\tWestVac Biopharma is also accelerating the development of the second-generation recombinant COVID-19 vaccine (Sf9 cells) in response to the continuous emergence of mutated strains such as Delta and Omicron strains. The vaccine belongs to the latest fifth generation vaccine technology (fully synthetic vaccine), targeting the S-RBD protein of the COVID-19 mutant strain, the subunit vaccine antigen is precisely designed based on the structure, which can self-assemble into stable nanoparticles. The large-scale production of the vaccine uses internationally advanced insect cell production technology and is combined with oil-in-water emulsion adjuvant (MF59-like adjuvant) that can induce a stronger immune response. The vaccine can induce the production of high titers of neutralizing antibodies upon immunizing animals such as mice or monkeys. The neutralizing antibodies against the Omicron variant strain can reach a level of ten thousands (it means that the blood is diluted 10,000 times and still has the ability to block the virus from infecting cells). It was previously discovered that the vaccine has a level of ten thousands neutralizing antibodies that completely inhibits Brazilian strains, South African strains, Delta strains and other mutant strains of Euvirus, suggesting that the vaccine is a universal COVID-19 against multiple mutant strains. It is also the first COVID-19 vaccine announced internationally that has high titers of neutralizing antibodies against the Omicron mutant strain. At present, the application materials have been submitted to the National Medical Products Administration in August, 2021, and it is expected to officially enter clinical trials in early 2022.
\r\n\t\t\r\n\t\tIn order to improve the safety and accessibility of the vaccine, WestVac Biopharma has also developed a nasal spray vaccine against COVID-19 variants, improving efficiency of protection by inducing nasal mucosal immunity. On the basis of the extensive research, the nasal spray type was selected to induce strong immune response. After two immunizations, rabbits can be induced to produce more than one hundred thousand binding antibodies, and there are obvious neutralizing antibodies. Additionally, the company is also in the process of developing the new oral anti-COVID-19 drug<\/a> and the mRNA COVID-19 vaccine, both of which have been shown to have good in vivo safety and activity.\r\n\t\t","text_promotion":"WestVac BioPharma Co., Ltd. (hereinafter referred to as \"WestVac BioPharma\") is an innovative biopharmaceutical enterprise integrating vaccine R&D, production and sales. The company’s registered capital is 1.242 billion yuan. The company is located in Chengdu Tianfu International Bio-town. WestVac Biopharma has a mature insect cell expressed recombinant protein platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine and immunotherapy platform. The company is committed to the development and production of a variety of innovative vaccines and immunotherapy products.
\r\n\t\t\r\n\t\tWestVac Biopharma has built a production base with an annual production capacity of 600 million doses in Chengdu Tianfu International Bio-town. The layout of production line is optimized, the production process is scientific and safe, and the production equipment is basically made in China. The company has completed the construction and verification of GMP production workshop, and obtained the \"Drug Manufacturing License\". In addition, Guangzhou production base with an annual capacity of 500 million doses is also under construction.
\r\n\t\t\r\n\t\tIn terms of production, quality, operations management, etc., WestVac Biopharma has introduced advanced talents from well-known domestic and international vaccine companies, established a complete production and quality management system, has more than 300 employees to ensure that large scale production of vaccines can proceed smoothly.
\r\n\t\t\r\n\t\tWestVac Biopharma has also established a good communication with many international organizations such as the World Health Organization (WHO), Gates Foundation, PATH, The Coalition for Epidemic Preparedness Innovations (CEPI) and so on. The company has submitted an application for emergency use of COVID-19 vaccine (EUL) to the World Health Organization (WHO), hoping to contribute to global COVID-19 prevention and control.\r\n\t\t","westvac":"WestVac Biopharma","more":"Read More","home_url":"en.html","news_url":"en\/news.html","latest_news":"Latest News","our_team":"Our Team","copyright":"© 2021 WestVac Biopharma Co.,Ltd. All rights reserved","join_msg":"Please send your resume to hr@westvacpharma.com","join_addr":"Address","join_edu":"Education","join_exp":"Experience","q1":"Quarter 1st","q2":"Quarter 2nd","q3":"Quarter 3rd","q4":"Quarter 4th","":"","wyq":"Yuquan Wei","wyq_des":"Chairman, General Manager, Professor of Oncology, Academician of the Chinese Academy of Sciences, former Vice President of Sichuan University, Director of the Clinical Oncology Center and Director of the State Key Laboratory of Biotherapy, West China Hospital, Chairman of the Chinese Medical Biotechnology Association, Head of the National Biotherapy Collaborative Innovation Center, National Comprehensive Head of the technology platform for new drug research and development, chief scientist of the \"973\" project of the Ministry of Science and Technology, head of the National Natural Science Foundation of China is innovative research group, co-editor of Signal Transduction and Targeted Therapy, associate editor of Human Gene Therapy, associate editor of Current Molecular Medicine, Current Cancer Drug Targets. He is responsible for the editorial board of the Asian region, and the editorial board of Scientific Reports and other international magazines. The second batch of specially-appointed professors in the \"Major Talents Program\" of the Ministry of Education, winner of the National Science Fund for Distinguished Young Scholars in 1997, candidates for the first and second levels of the National \"One Hundred Thousand Talents Project\", and the 15th \"863\" Bioengineering in the field of biology and agricultural technology, Leader of the technical subject expert group, member of the 12th Five-Year \"863\" biotechnology drug subject expert group in the field of biology and medicine, former vice president of the Chinese Medical Association, former executive deputy director of the Department of Biomedicine of the Science and Technology Committee of the Ministry of Education.","ljin":"Ellen Liu","ljin_des":"Vice Chairman. Before joined WestVac, Madame Liu was Managing Director, Investment Banking Division of Merrill Lynch Asia, Executive Director of Goldman Sachs China Team, Director for Business Development of Pricewaterhouse Coopers. Madame Liu is Vice President of Youth Committee of All-China Federation of Returned Overseas Chinese, Co-founder of Hong Kong Association of Chinese Returned Scholars Limited, President of Sichuan University Hong Kong Alumni Association.","yjl":"Jinliang Yang","yjl_des":"Executive Deputy General Manager, Professor. The main research areas are antibody drug development, tumor immune gene therapy and synthetic biology.","ww":"Wei Wang","ww_des":"Executive Deputy General Manager, Ph.D., Researcher, Doctoral Mentor. Currently working at the State Key Laboratory of Biotherapy\/Biotherapy Collaborative Innovation Center\/National Comprehensive New Drug Development Platform, Director of the Immunogene Cell Therapy Office, West China Hospital of Sichuan University; Editor of Gene Therapy, PloS ONE magazine. In recent years, Wang Wei has been engaged in the development and application of immunotherapeutic biological products, mainly focusing on the basic research and applied research of immunotherapeutic biological products such as the new coronary pneumonia vaccine; he has experience in the management and operation of the industrialization of scientific research projects.","wzl":"Zhenling Wang","wzl_des":"Deputy General Manager, Ph.D. in Clinical Medicine. Focus on the research and development of vaccines and new antibiotics against drug-resistant microorganisms. In charge of vaccine clinical trials at present.","lgw":"Guangwen LU","lgw_des":"Ph.D., Professor at the State Key Laboratory of Biotherapy, Sichuan University.
\r\n The main focus of Guangwen Lu’s research group include:
\r\n 1. The pathogenesis of virus infection.
\r\n 2. The interplays between viruses and host.
\r\n 3. Structural and functional features of virus entry.
\r\n 4. The development of new antiviral strategies.
\r\n He has thus-far published more than 50 peer-reviewed papers in international journals, including Nature, Cell Host & Microbe, Nature Structural Molecular Biology, PNAS, Nature Communications, etc.","yl":"Li Yang","yl_des":"Deputy General Manager, Researcher, Doctoral Mentor, Ph.D., State Key Laboratory of Biotherapy, West China Hospital, Sichuan University. Winner of the New Century Excellent Talents Program of the Ministry of Education (2009); Winner of the Sichuan Outstanding Youth Academic and Technical Leader Funding Program (2012); National High-level Talent Special Support Program Leader (2014); National \"Ten Thousand Talents Program\" leader (2016); Leading Talents of Health and Family Planning in Sichuan Province (2017); Leading Talents of Tianfu Innovation in the \"Tianfu Ten Thousand Talents Program\" of Sichuan Province (2018). The current deputy secretary-general of China Medical Biotechnology Association.Engaged in the research and development of biotechnology drugs for major diseases, published 51 SCI papers as first\/corresponding authors, applied for 50 invention patents (3 PCT), and received 8 national-level project funding.","ljiong":"Jiong Li","ljiong_des":"Dr. Jiong Li graduated from Sichuan University. She is a professor and Doctoral Mentor at the National Center for Biotherapy of West China Hospital of Sichuan University. Winner of Sichuan Outstanding Youth and WuXi AppTec Life Chemistry Research Award. More than 20 years of experience in the research and development of recombinant protein drugs CMC, rich experience in process development, formulation research, GLP preclinical research and GMP clinical trial sample production. She has published more than 80 SCI papers, applied for authorization of more than 10 international PCT and national invention patents, and is responsible for a number of national-level projects.","wxw":"Xiawei Wei","wxw_des":"Ph.D., is a researcher at the State Key Laboratory of Biotherapy, Sichuan University, a Doctoral Mentor, and deputy director of the National Geriatrics Clinical Research Center. Served as a member of the Cancer Gene & Cell Therapy Committee and Nanoagents & synthetic formulations Committee of the American Society of Gene Cell Therapy, and the youth chairperson of the Asia Pacific Gene\/Cell Therapy Association. Served as an Editorial Board Member of 5 SCI journals, published more than 40 SCI papers, and undertook regional key projects of the National Natural Science Foundation of China.","yjy":"Jingyun Yang","yjy_des":"Ph.D., Major in Biotherapy of major human diseases at the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, focusing on tumor vaccine, tumor immunogenic therapy, tumor cell biology, and recombinant protein drug research and development. He published a research paper A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity in Nature as the first author, and more than 10 SCI research papers in Signal Transduct Target Therapy, Theranostics, EBiomedicine, iScience, ACS Appl Mater Interinterfaces and other journals.","sgb":"Guobo Shen","sgb_des":"Ph.D., Associate Researcher. His main research areas are disease target screening, tumor biotherapy, and recombinant protein drug research and development. He has presided over the \"863\" project and a number of natural science fund projects. He has published more than 50 research papers in international journals such as Cell Res., STTT, J. Immunol., Nat. cell biol., and participated in the application of 2 national invention patents.","zzw":"Zhiwei Zhao","zzw_des":"Deputy General Manager, Ph.D. in Cell Biology, Senior Engineer, 2013 \"Double Hundred Plan\" innovative talent in Yantai City, Shandong Province, is mainly good at the research and development and production of virus vaccines and tumor immune preparations.","edu":"Not Specified","exp":"Not Specified","posted":"Posted","salary":"Negotiation","destitle":"Job Description","destitle1":"Task Description","destitle2":"Job Requirement","new1":"Company News","new2":"Notice Announcement","new3":"Popular Science","new4":"Westvac Video","new5":"Industry Dynamics","all":"All","product1":"Product","product2":"Pharmacovigilance","team1":"Expert Team","team2":"Leadership Team","contact_group":"Headquarters","contact_address":"Add","contact_address_text":"No.552 Fenghuang Road, Chengdu Tianfu International Bio-Town, Chengdu, Sichuan, P.R. China","contact_tel":"Tel","contact_tel_text":"028-60655060","contact_email":"E-mail","contact_email_text":"westvac@westvacpharma.com","contact_hr":"Human Resources","contact_hr_text":"hr@westvacpharma.com","contact_mr":"Media Relations","contact_mr_text":"pr@westvacpharma.com","contact_bd":"Business Development","contact_bd_text1":"bd@westvacpharma.com","contact_bd_text2":"marketing@westvacpharma.com","contact_pv":"Pharmacovigilance","contact_pv_text":"clinical_pv@westvacpharma.com","culture_brand":"Corporate Philosophy","culture_brand_text":"WE Initiate Science & Technology Value，Always for Caring","culture_mission":"Mission","culture_mission_text":"Extensively explore and innovate to prevent and fight human disease","culture_vision":"Vision","culture_vision_text":"Bring innovative vaccines and immunotherapies from China to the world
for the benefit of mankind","culture_core_values":"Core Values","culture_core_c":"Creation","culture_core_c_info":"Creation goes from challenging conventions to making breakthroughs.
This requires us to focus on scientific research, overcoming challenges and seeking breakthroughs.","culture_core_c1":"Focus on scientific research","culture_core_c2":"Overcome challenges","culture_core_c3":"Seek breakthroughs","culture_core_a":"Acceleration","culture_core_a_info":"Acceleration is responding quickly to changing environments.
This requires us to be effective, flexible and to pursuit the best.","culture_core_a1":"Be effective","culture_core_a2":"Be flexible","culture_core_a3":"Pursuit the best","culture_core_r":"Responsibility","culture_core_r_info":"Each life should be watched and cared for.
This requires us to value health, manage business with integrity and ensure quality.","culture_core_r1":"Value health","culture_core_r2":"Manage business with integrity","culture_core_r3":"Ensure quality","culture_core_e":"Excellence","culture_core_e_info":"In order to prevent and fight human diseases,we must do our best.
This requires us to think big, gather talent and intellect , and measure outcomes.","culture_core_e1":"Think big","culture_core_e2":"Gather talent and intellect","culture_core_e3":"Measure outcomes","job_status_0":"Closed","job_status_1":"Recruiting"});